Synergy Pharmaceuticals (FRA:S90) Accounts Payable & Accrued Expense : €28.59 Mil (As of Sep. 2018)

View and export this data going back to 2012. Start your Free Trial

What is Synergy Pharmaceuticals Accounts Payable & Accrued Expense?

Synergy Pharmaceuticals's quarterly accounts payable & accrued expense declined from Mar. 2018 (€30.40 Mil) to Jun. 2018 (€24.48 Mil) but then increased from Jun. 2018 (€24.48 Mil) to Sep. 2018 (€28.59 Mil).

Synergy Pharmaceuticals's annual accounts payable & accrued expense increased from Dec. 2015 (€17.97 Mil) to Dec. 2016 (€27.90 Mil) and increased from Dec. 2016 (€27.90 Mil) to Dec. 2017 (€32.23 Mil).

Synergy Pharmaceuticals Accounts Payable & Accrued Expense Historical Data

The historical data trend for Synergy Pharmaceuticals's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synergy Pharmaceuticals Accounts Payable & Accrued Expense Chart

Synergy Pharmaceuticals Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

11.44

14.87

17.97

27.90

32.23

Synergy Pharmaceuticals Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															26.82	32.23	30.40	24.48	28.59

Synergy Pharmaceuticals Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Synergy Pharmaceuticals (FRA:S90) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Synergy Pharmaceuticals Inc (FRA:S90) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

420 Lexington Avenue, Suite 2012, New York, NY, USA, 10170

Website

http://www.synergypharma.com

Synergy Pharmaceuticals Inc functions in the healthcare sector based in the United States. It focusses on developing therapies to combat gastrointestinal diseases. The company's basic ingredient is the uroguanylin analog, which it employs in its products candidates such as plecanatide and dolcanatide. Plecanatide is a once-daily tablet, which addresses chronic idiopathic constipation and the irritable bowel syndrome. Dolcanatide is meant to cure inflammatory bowel disease by aiding the process of digestive breakdown.

Synergy Pharmaceuticals (FRA:S90) Headlines

No Headlines